

# 1 Proteomics Uncovers Immunosuppression in COVID- 2 19 Patients with Long Disease Course

3 Shaohua Tang <sup>1#</sup>, Rui Sun <sup>2,3#</sup>, Qi Xiao <sup>2,3#</sup>, Tingting Mao <sup>1#</sup>, Weigang Ge <sup>2,3#</sup>,  
4 Chongquan Huang <sup>1#</sup>, Meng Luo <sup>2,3,4</sup>, Liujiia Qian <sup>2,3</sup>, Hao Chen <sup>2,3</sup>, Qiushi Zhang <sup>2,3</sup>,  
5 Sainan Li <sup>2,3</sup>, Wei Liu <sup>2,3,5</sup>, Shufei Li <sup>1</sup>, Xueqin Xu <sup>1</sup>, Huanzheng Li <sup>1</sup>, Lianpeng Wu <sup>1</sup>,  
6 Jianyi Dai <sup>1</sup>, Huanhuan Gao <sup>2,3</sup>, Lu Li <sup>2,3</sup>, Tian Lu <sup>2,3</sup>, Xiao Liang <sup>2,3</sup>, Xue Cai <sup>2,3</sup>, Guan  
7 Ruan <sup>2,3</sup>, Kexin Liu <sup>4</sup>, Fei Xu <sup>5</sup>, Yan Li <sup>6</sup>, Yi Zhu <sup>2,3\*</sup>, Jianping Huang <sup>1\*</sup>, Tiannan Guo  
8 <sup>2,3,7\*</sup>

9 <sup>1</sup> Wenzhou Central Hospital, Dingli Clinical Medical School of Wenzhou Medical University,  
10 Wenzhou, 325000, Zhejiang, China;

11 <sup>2</sup> Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences,  
12 Westlake University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China;

13 <sup>3</sup> Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 Shilongshan  
14 Road, Hangzhou 310024, Zhejiang Province, China;

15 <sup>4</sup> Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University,  
16 Dalian 200335, Liaoning, China

17 <sup>5</sup> Department of Anatomy, College of Basic Medical, Dalian Medical University, Dalian, China

18 <sup>6</sup> Department of Anatomy and Physiology, College of Basic Medical Sciences, Shanghai Jiao  
19 Tong University, No.280 Chongqing South Road, Shanghai 200025, China

20 <sup>7</sup> Lead Contact

21 # These authors contribute equally

22 \* Correspondence: [zhuyi@westlake.edu.cn](mailto:zhuyi@westlake.edu.cn) (Y.Z.); [hjpxxy006@163.com](mailto:hjpxxy006@163.com) (J.H.);  
23 [guotiannan@westlake.edu.cn](mailto:guotiannan@westlake.edu.cn) (T.G.)

## 25 Abstract

26 Little is known regarding why a subset of COVID-19 patients exhibited  
27 prolonged positivity of SARS-CoV-2 infection. Here, we present a longitudinal  
28 sera proteomic resource for 37 COVID-19 patients over nine weeks, in which  
29 2700 proteins were quantified with high quality. Remarkably, we found that  
30 during the first three weeks since disease onset, while clinical symptoms and  
31 outcome were indistinguishable, patients with prolonged disease course  
32 displayed characteristic immunological responses including enhanced Natural  
33 Killer (NK) cell-mediated innate immunity and regulatory T cell-mediated  
34 immunosuppression. We further showed that it is possible to predict the  
35 length of disease course using machine learning based on blood protein  
36 levels during the first three weeks. Validation in an independent cohort  
37 achieved an accuracy of 82%. In summary, this study presents a rich serum  
38 proteomic resource to understand host responses in COVID-19 patients and  
39 identifies characteristic Treg-mediated immunosuppression in LC patients,  
40 nominating new therapeutic target and diagnosis strategy.

41 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 42 INTRODUCTION

43 COVID-19 caused by the SARS-CoV-2 virus is an ongoing pandemic  
44 spreading all over the world. About 80% of COVID-19 patients exhibit mild  
45 clinical symptoms including fever and cough, while ~20% of patients  
46 deteriorate to life-threatening severe or critical conditions (Wu and  
47 McGoogan, 2020). Multiple studies have investigated the clinical course and  
48 pathogenesis (To et al., 2020; Yang et al., 2020; Zhou et al., 2020) and  
49 molecular changes (Messner, 2020; Shen, 2020; Wu et al., 2020) of severe or  
50 critical cases.

51 What remains largely unknown is the substantial diversity of COVID-19  
52 patients in terms of disease course. In a recent report, the median interval of  
53 COVID-19 patients from onset to clinical recovery was 20 days, with the  
54 longest disease course of 37 days (Zhou et al., 2020). According to our  
55 clinical treatment of 37 COVID-19 patients, some patients exhibited  
56 surprisingly prolonged virus infection. The longest disease course we have  
57 observed thus far is 107 days (P33, a 55-year-old male) as of 17 May 2020.  
58 Little is known about the causes of persistent virus infection and how he could  
59 be effectively treated.

60 Here we report a longitudinal and in-depth proteomic profiling of 37  
61 COVID-19 patients with short and long disease courses. We analyzed the  
62 sera proteomes collected over nine weeks for both patients with short disease  
63 course (SC) who turned negative for the virus infection in less than 22 days,  
64 and LC patients who remained positive for 22 days or longer. We have also  
65 analyzed the sera proteomes of 35 non-COVID-19 patients with flu-like  
66 symptoms as controls. 2700 proteins were quantified with high quality, offering  
67 a rich resource to understand the dynamic disease course of COVID-19  
68 patients in response to virus infection. Our data showed characteristic  
69 immune responses between the SC and LC patient groups. Remarkably, the  
70 data suggest regulatory T cell (Treg)-mediated immunosuppression was  
71 specifically activated in LC patients. We also showed that it is possible to  
72 predict the disease course of COVID-19 patients by measuring the  
73 characteristic protein levels from blood samples collected in the first three  
74 weeks since disease onset using a machine learning model. This study not  
75 only presents a rich resource to study the COVID-19 host responses, but also  
76 nominates novel therapeutic and diagnostic strategies for COVID-19 patients  
77 with prolonged infection positivity.

78

## 79 RESULTS AND DISCUSSION

### 80 Patients, samples and proteomics

81 We procured 37 COVID-19 patients in this study of which 35 were typical  
82 and two were severe cases (Table 1, Table S1), including 19 males and 18  
83 females, with a median age of 48 years. The median duration of disease in

84 this cohort, as defined in Methods, was 22 days. These patients were divided  
85 into two groups based on the length of their disease course (Figure 1). The  
86 SC group comprised 17 patients with a disease course shorter than 22 days.  
87 The other 20 patients were defined as LC group. Interestingly, one of the  
88 severe cases was classified as SC, while the other severe case was in the LC  
89 group (Figure 1).

90 These two groups (SC and LC) were indistinguishable based on clinical  
91 symptoms. The median age of SC patients was 43.2 years (range, 27-67  
92 years) for SC patients, and 49.0 years (range, 2-84 years) for LC patients.  
93 The Wilcox t-test showed no significant age difference between the SC and  
94 LC patient groups (Figure S1A). Clinical treatment of both groups of patients  
95 was not significantly different by Fisher's exact test (Figure S1B, Table 1),  
96 indicating that the different lengths of disease course were unlikely due to  
97 existing therapeutics. Routine blood test data for the two groups showed no  
98 significant difference either (Figure S1C). We analyzed an additional 35 non-  
99 COVID-19 patients with flu-like symptoms as controls (Table 1, Table S1, and  
100 Figure 1B).

101 We performed in-depth profiling for sera proteome collected from each  
102 patient over nine weeks using TMTpro 16plex-based data-dependent  
103 acquisition mass spectrometry (Thompson et al., 2019). 14 high-abundance  
104 blood proteins were largely depleted to enhance the ability to measure low-  
105 abundance proteins. Each TMT-labeled peptide mixture was fractionated into  
106 26-30 fractions for comprehensive discovery proteomic analysis (Figure 1A). A  
107 total of 224 depleted serum samples were analyzed using TMT-based  
108 proteomics (Figure 1). Samples were randomly distributed into 18 batches.  
109 We also analyzed 44 technical replicates for randomly selected samples in  
110 each batch (Figure S2A). Each pool of TMT-labeled peptides was further  
111 fractionated into 26-30 fractions using high-pH reverse phase liquid  
112 chromatography (RPLC) and analyzed by LC-MS/MS using a 60-min RPLC  
113 gradient. The median coefficient of variance (CV) among MS/MS technical  
114 replicates was 0.19 (Figure S2B). After excluding proteins with missing values  
115 in over 80% of samples, we presented quantitative levels of 2700 proteins  
116 across 268 sera samples with relatively high degrees of quantitative accuracy  
117 (Table S2A).

118

### 119 **Complex immunity in the LC patients**

120 To investigate host response differences in the serum proteome data set  
121 from the SC and LC patients, we performed a pairwise comparison of the  
122 proteins quantified in these two groups at each week over nine weeks. We  
123 then combined the regulated proteins at each week, leading to the  
124 identification of 921 dysregulated proteins (Table S2B), of which 405 proteins  
125 were functionally annotated in the UniProt database. We firstly used only GO  
126 biological process, KEGG and Reactome pathway enrichment using 405  
127 proteins, and found that most pathways were related to immunity and

128 metabolism (Figure S3).

129 Generally, our data showed that the first week is the inflammatory  
130 response period, featured by activation of redox and amino acid metabolic  
131 processes. In the following three weeks, more pathways involved in adaptive  
132 immunity and glycometabolism were activated. Interestingly, some sex  
133 hormone associated pathways were also enriched, such as fertilization and  
134 response to estradiol. From fifth to ninth week, the two patient groups  
135 displayed difference in pathways involved in tissue remodelling and repair,  
136 apoptosis and sulfur compound catabolic process.

137 We then focused on the immunity-related pathways at each time point as  
138 shown in Figure 2A. For SC patients, they showed upregulated platelet  
139 degranulation in the first week, followed by activation of antigen presentation  
140 in the following two weeks. Leukocyte degranulation was activated in the third  
141 week. In the sixth week, SC patients showed upregulation of serum proteins  
142 involved in tissue remodeling (Figure 2A) as signs of recovery. LC patients  
143 displayed much more complex serum proteome dynamics. During the first  
144 week, both platelet degranulation and upregulation of Treg vs Teff were  
145 activated. Activation of antigen presentation occurred in the second week. The  
146 complement system was also activated from the second week. Interestingly,  
147 the regulatory T cell (Treg) activation pathway was enriched in the first two  
148 weeks and the fifth week, suggesting immunosuppression occurred early in  
149 these patients. From the fourth week, leukocyte migration was enriched.  
150 Tissue repair was enriched only in the eighth week, followed by the  
151 complement system in the ninth week (Figure 2A). These data suggest that  
152 immunological responses during the first three weeks may be critical in  
153 determining the length of the disease course. During this period, both innate  
154 and adaptive immunity were activated in SC patients, while in contrast, LC  
155 patients showed signs of Treg-mediated immunosuppression in addition to  
156 innate and adaptive immunity.

157 Our data also underscored the proteins involved in the above-mentioned  
158 pathways as shown in Figure S3. In SC patients, a secreted protein, the  
159 soluble scavenger receptor cysteine-rich domain-containing protein (SSC5D)  
160 was highly expressed in the second week (Figure S4). SSC5D is highly  
161 expressed on monocytes and activated lymphocytes rather than naïve  
162 immune cells, and mediates both innate and adaptive immunity (Goncalves et  
163 al., 2009), suggesting activated immune responses to virus infection. In the  
164 third week, another upregulated protein in SC patient sera was non-secretory  
165 ribonuclease (RNASE2), a chemoattractant for dendritic cells. RNASE2 is  
166 reported to participate in antigen presentation (Yang et al., 2003), and may  
167 play a role in the adaptive immunity against SARS-CoV-2 (Figure S4). In the  
168 fourth week, a pro-inflammatory factor, chromogranin-A (CHGA), was  
169 upregulated in the sera in SC patients. CHGA highly expressed on the  
170 secretory cells to regulate catecholamine secretion which is associated with  
171 serum CHGA (di Comite et al., 2006) and is reported to activate pro-

172 inflammatory M1 macrophages and inhibit anti-inflammatory M2 macrophages  
173 (Eissa et al., 2018). In the sixth week, serum amyloid P-component (APCS)  
174 was upregulated in SC patient sera (Figure S4), suggesting clearance of  
175 damaged circulating cells and enhanced angiogenesis.

176 In LC patients, positive regulators for immune response were found to be  
177 activated. Hepatocyte growth factor-like protein (MST1) was upregulated in  
178 the second week (Figure 2A). MST1 is required for thymocyte migration and  
179 antigen recognition (Ueda et al., 2012). Besides, Golgi-associated plant  
180 pathogenesis related protein 2 (GLIPR2), associated with the migration of T  
181 and B lymphocytes, was up-regulated in the fourth week (Figure S4). In the  
182 following week, we observed upregulation of two immunosuppressive factors,  
183 namely fibroleukin (FGL2) and programmed cell death 1 ligand 2  
184 (PDCD1LG2). FGL2 negatively regulates dendritic cell antigen presentation  
185 and T cell differentiation, especially the secreted FGL2 (Hu et al., 2016). It  
186 was upregulated in LC patients and further increased during recovery from  
187 COVID-19 (Figure S4). PDCD1LG2 negatively regulates T cell activation  
188 (Brown et al., 2003), and followed similar dynamics over the disease course to  
189 FGL2 (Figure S4). In the eighth week, tissue remodeling associated proteins,  
190 such as von Willebrand factor (VWF), were upregulated in the LC group,  
191 suggesting recovery from COVID-19. Besides, our data show that the  
192 complement system may play important roles in LC patients during the entire  
193 disease course. In the second week, the most enriched pathway involving the  
194 upregulation of C5 was the complement cascade (Figure 2A). In the last  
195 week, C8A and other complement system proteins remained upregulated  
196 (Figure S4). Complement activation was reported in our previous study of  
197 COVID-19 sera (Shen, 2020). The complement cascade could also contribute  
198 to immunosuppression (Kemper et al., 2003) and might be a potential  
199 therapeutic target for COVID-19 (Cao, 2020).

200 Altogether, negative regulator factors and innate immune performed more  
201 active might result in longer disease course.

202

### 203 **Characteristic protein dynamics in the LC patients**

204 Next, we investigated whether the differentially expressed proteins  
205 between SC and LC patients were unique to COVID-19 disease by making  
206 comparison between COVID-19 and non-COVID-19 patients with flu-like  
207 symptoms (Ctrl, Figure 1B). We first analyzed the temporal dynamics of the  
208 2700 proteins using Mfuzz (Kumar and Mattias, 2007) for SC and LC patients.  
209 1746 proteins, grouped in eight clusters in the SC and LC patient groups  
210 (Table S2C), were consistently dysregulated over time compared to the  
211 control group (Figure S5A-B). Four characteristic protein clusters were  
212 enriched in the two patient groups (Figure S5C). In the meantime, 774  
213 proteins were identified to be differentially expressed in COVID-19 patients  
214 compared to the Ctrl group (Table S2D). By overlapping the two above-  
215 mentioned protein shortlists with the 921 dysregulated proteins between SC

216 and LC patients, our data were narrowed down to 207 proteins which fulfill the  
217 following three criteria: a) differentially expressed between SC and LC; b)  
218 consistently up- or down-regulated over time; c) COVID-19 disease specific  
219 (Figure 2B). Out of 207 proteins, 97 proteins were functionally annotated by  
220 the Ingenuity Pathway Analysis (IPA) software tool (Table S2E).

221 These proteins were segregated into two major groups based on their  
222 expression across all nine time points during the disease course (Figure 2C).  
223 The first group of 80 proteins showed increased expression over time. SC  
224 patients exhibited earlier elevation of these proteins, while LC patients  
225 exhibited delayed increase (Figure 2C). Four major pathways were enriched  
226 in this protein group, namely acute phase response, LXR/RXR activation,  
227 agranulocyte adhesion and diapedesis, and actin cytoskeleton signaling  
228 (Figure 2D). Also, the coagulation and complement systems were also  
229 enriched in this protein group. Acute phase response signaling, coagulation  
230 and complement systems are associated with innate immunity, while actin  
231 cytoskeleton signaling is associated with leukocyte migration in adaptive  
232 immunity.

233 The second group of 17 proteins showed decreasing expression over  
234 time. SC patients showed an earlier decrease than LC patients (Figure 2E).  
235 These proteins were mapped to enriched pathways including metabolic  
236 processes such as myo-inositol biosynthesis, glycolytic shunt and glutamyl  
237 cycle (Figure 2E).

238 Next, we calculated the median expression level of the two groups of  
239 proteins and present them in boxplots (Figure 2D, 2E). For the first group of  
240 proteins, generally SC patients showed lower protein expression than LC  
241 patients in the first three weeks, but the expression was dramatically elevated  
242 from the fourth week and maintained thereafter at a high level for several  
243 weeks (Figure 3D). This agrees with clinical data that all these SC patients  
244 tested negative for SARS-CoV-2 nucleic acid after the third week. In contrast,  
245 LC patients showed a higher degree of longitudinal diversity in the trends of  
246 expression of these proteins, probably partly due to their variable clinical  
247 recovery trajectories. Expression of the first group of proteins in the first four  
248 weeks was relatively stable but dramatically increased in the fifth week,  
249 followed by a decrease from the sixth to the seventh week, and a second rise  
250 in the eighth week (Figure 2D).

251 Interestingly, the expression of the second group of proteins displayed an  
252 opposite trend compared to the first group (Figure 2E). Protein expression of  
253 the SC patients started to decrease during the 4<sup>th</sup> week and continued to  
254 decrease until the last time point; while the LC patients showed high protein  
255 expression level till the fifth week, with a shallow decrease beginning in the  
256 sixth week (Figure 2E).

257

### 258 **Dysregulated leukocyte migration and IFG/redox homeostasis**

259 Pathway analysis of the two protein groups mentioned above highlighted

260 leukocyte migration and IGF/redox homeostasis (Figure 3).

261 Representative proteins related to leukocyte migration included beta-  
262 defensin 1 (DEFB1), selectin P (SELP), ezrin (EZR) and moesin (MSN)  
263 (Figure 3A). DEFB1 is a ligand for the chemokine receptor CCR6 and a  
264 positive upstream regulator of Th17 (Wojtowicz et al., 2015). SC patients  
265 exhibited high expression of DEFB1 in the first three weeks, but it decreased  
266 from the fourth week when patients became negative in the nucleic acid test  
267 (Figure 3A). In contrast, LC patients exhibited a delayed increase of this  
268 protein until the third week (Figure 3A), suggesting delayed activation of Th17  
269 in LC patients. Leukocyte extravasation occurs in two sequential steps,  
270 among which SELP participates in the first process of leukocyte adhesion to  
271 the endothelial surface (Vicente-Manzanares and Sanchez-Madrid, 2004). In  
272 SC patients, expression of SELP was relatively low in the first three weeks,  
273 and then increased significantly in the fourth week and maintained at a high  
274 level until the ninth week (Figure 3A). SELP increase in LC patients, however,  
275 was much shallower, and peaked as late as the eighth week, in line with their  
276 prolonged disease course (Figure 3A). The complex of ezrin-radixin-moesin  
277 (ERM) links cytoskeleton with membrane adhesion molecules; however,  
278 moesin (MSN) and ezrin exert opposite functions (Ivetic et al., 2002). Our data  
279 showed that EZR was maintained at a relatively high level during the first  
280 three weeks in SC patients and then decreased thereafter (Figure 3A).  
281 Interestingly, in these patients, MSN showed an opposite trend in which  
282 expression increased from the fourth week and thereafter was maintained at a  
283 relatively high level. In LC patients, the change of ERM components showed a  
284 similar pattern but with a delayed transition point (Figure 3A).

285 In addition to the proteins directly involved in immunity, our data also  
286 highlighted metabolic pathways such as the IGF/redox homeostasis pathway  
287 which is critical in maintaining the microenvironment for immune responses  
288 (Figure 3A). We narrowed our focus to proteins involved in IGF/redox  
289 homeostasis namely insulin-like growth factor 1 (IGF1), superoxide dismutase  
290 (SOD1), glutathione synthetase (GSS) and 5-oxoprolinase (OPLAH) (Figure  
291 3A). IGF1 promotes the proliferation of Treg cells (Anguela et al., 2013). In SC  
292 patients, expression of IGF1 increased from the second to the sixth week,  
293 followed by a dramatic decrease in the seventh week, in line with the recovery  
294 of these patients (Figure 3A). However, in LC patients, expression of IGF1  
295 slightly upregulated than in SC patients and increased until the eighth week,  
296 followed by a slow decline thereafter. The expression of IGF1 is higher in the  
297 LC patients than SC patients in the initial and the end of the disease stage  
298 (Figure 3A). Infection-induced ROS was reported to accelerate the  
299 accumulation of Treg cells, which led to immunosuppression (Yang et al.,  
300 2013). ROS may also induce the expression of SOD1 in the mitochondria to  
301 reduce ROS as negative feedback (Ma, 2013). Our data showed that the  
302 expression of SOD1 peaked earlier in SC patients (fourth week) than that in  
303 the LC patients (fifth week, Figure 4A), indicating that clearance of infection-

304 induced ROS in SC patients occurred earlier than in LC patients. GSS and  
305 OPLAH are both involved in the glutamyl cycle that maintains redox  
306 homeostasis (Forman et al., 2009). In the glutamyl cycle, GSS catalyzes the  
307 generation of reduced glutathione (GSH). OPLAH catalyzes the conversion of  
308 5-oxoproline into glutamate and indirectly enhances the consumption of GSH.  
309 Our data showed that GSS was upregulated in the fourth week in SC patients,  
310 about one week earlier than its increase in LC patients (Figure 3A). In  
311 contrast, the downregulation of OPLAH began in the fourth week in SC  
312 patients, while in LC patients it did not substantially decrease until the eighth  
313 week (Figure 3A). The timely upregulation of GSS and downregulation of  
314 OPLAH might contribute to the elimination of infection-induced ROS in SC  
315 patients, while their delayed modulation may have contributed to the  
316 prolonged disease course of LC patients.

317

### 318 **Treg-mediated immunosuppression and crosstalk with other immune** 319 **cells in the LC patients**

320 The leukocyte migration and IGF/redox homeostasis pathway may  
321 modulate the activities of Th17 and Treg cells (Figure 3B). Th17 cells are a  
322 subset of T helper (Th) cells. Th17 cells are differentiated from CD4<sup>+</sup> T cells  
323 with a pro-inflammatory role upon infection when IL6 is relatively high (Kimura  
324 and Kishimoto, 2010). The upregulation of IL-6 has been reported as one of  
325 the most critical cytokines in severe COVID-19 patients (Ruan et al., 2020).  
326 Our data suggested that activation of Th17 cells may play a role in T cell  
327 immunity in COVID-19. Opposite to Th17 cells, Treg cells are induced from  
328 CD4<sup>+</sup> T cells when IL-6 is relatively low and they suppress immunity (Kimura  
329 and Kishimoto, 2010).

330 Our data showed longitudinal down-regulation of DEFB1, an upstream  
331 activator of Th17. LC patients showed a delayed decrease of DEFB1,  
332 suggesting delayed activation of Th17. IGF1 promotes Treg cells. A higher  
333 level of IGF1 in the LC patients suggested aberrant Treg-mediated  
334 immunosuppression in the LC patients (Figure 3A). Besides, infection-induced  
335 ROS, regulated by GSS and OPLAH, may also trigger Treg-mediated  
336 immunosuppression in LC patients as discussed above.

337 We next applied flow cytometry to analyze the CD127<sup>-</sup>CD25<sup>+</sup> Treg cell  
338 subpopulation in peripheral blood samples collected from disease onset to the  
339 fourth week (SC: 17 patients, 30 samples; LC: 17 patients, 22 samples). The  
340 data showed that the number of CD127<sup>-</sup>CD25<sup>+</sup> Treg cells was significantly  
341 higher in LC patients than that in SC patients ( $p=0.006$ ), while the CD45<sup>+</sup>  
342 lymphocytes ( $p=0.306$ ) and CD3<sup>+</sup>CD4<sup>+</sup> T cells ( $p=0.871$ ) did not show a  
343 significant difference (Figure 4A). The data support the hypothesis that  
344 CD127<sup>-</sup>CD25<sup>+</sup> Treg-mediated immunosuppression may be induced in LC  
345 patients during the first few weeks. Inhibition of Treg cells could be a potential  
346 therapeutic approach for COVID-19 patients with long disease course.

347 More natural killer (NK) cells, especially the cytotoxic subset (CD3<sup>-</sup>



348 CD56<sup>+</sup>CD16<sup>+</sup>), were found in LC patients (Figure 4B). NK cells are a typical  
349 kind of cells in innate immunity. In the meantime, CD3<sup>-</sup>CD56<sup>-</sup>CD16<sup>-</sup> cells were  
350 found to be decreased in the LC group (Figure S6A-B). These cells are  
351 probably B cells, which is further supported by our finding that the antibody  
352 level of these patients were also decreased (Huang, 2020). The decrease of B  
353 cells may also be supported by the finding that NK cells can inhibit the B cell  
354 immunity through reducing neutralizing antibodies (Rydyznski et al., 2015).  
355 However, unfortunately we did not have sufficient sample to stain these  
356 reduced cells with markers for B cells to confirm their identity.

357 We then measured the key cytokines and growth factors such as IL-2, IL-  
358 4, IL-5, IL-6, IL-10, IL-17A, IFN- $\gamma$ , and TNF- $\alpha$  of clinical importance. They  
359 were measured using antibody-based method (SC: 17 patients, 30 samples;  
360 LC: 17 patients, 22 samples; Figure 5B and Figure S6C). Except for TNF- $\alpha$ ,  
361 other molecules showed no difference between SC and LC patients, probably  
362 because most patients in this study were non-severe cases (Figure 5B). TNF-  
363  $\alpha$  was found to be increases in the LC group, which might be associated with  
364 the upregulated NK cells.

365 However, in our proteomics data, we identified two key receptors for IL-6,  
366 namely the alpha subunit (IL6R) and the beta subunit (IL6ST) of the  
367 interleukin-6 receptor. These two subunits are jointly required to mediate IL-6  
368 signal transmission. Overall, LC patients expressed higher IL6ST than SC  
369 patients did (Figure 5). Interestingly, IL6R was upregulated in LC patients  
370 during the first four weeks followed by a decline thereafter. In SC patients,  
371 IL6R expression did not show the substantial change (Figure 5). This  
372 difference of IL6R expression trends may reflect transient activation of Th17  
373 during the prolonged disease course. We also detected the dynamics of two  
374 proteins, transforming growth factor beta-1 protein (TGFB1) and cytosol  
375 aminopeptidase (LAP3), which are associated with Treg function. LAP3 is one  
376 of the surface markers of Treg, and TGFB1 regulated Treg and Th17 (Oida et  
377 al., 2003). Similar to IL6ST, LAP3 also kept a higher level in the LC group  
378 across the disease course than in SC patients (Figure 5). TGFB1 showed no  
379 difference between the SC and LC patients (Figure 5).

380 Taken together, our data showed that NK cell-mediated innate immune  
381 and Treg-mediated immunosuppression were both activated in the LC group,  
382 while CD3<sup>-</sup>CD56<sup>-</sup>CD16<sup>-</sup> cells were decreased in the LC group, suggesting  
383 suppression of B cells which may be associated with decreased antibody  
384 level.

385

### 386 **Predictive model for the length of disease course**

387 The above analysis showed that SC and LC patients have different  
388 proteomic serological responses during the early phase of COVID-19 when  
389 the two groups of patients were clinically indistinguishable during the first few  
390 weeks (Figure S1). This raises the possibility of predicting disease course  
391 based on proteomic patterns during the early phase. To test this, we built a

392 random forest model using the serum proteomic data collected during the first  
393 three weeks. We included a total of 80 serum samples as a discovery dataset  
394 (Figure 6A) which were randomly divided into two groups: a 66-sample  
395 training dataset (30 patients and 66 samples) and a validation dataset (7  
396 patients and 14 samples). Next, a previously published cohort (39 patients  
397 and 39 samples) (Shen, 2020) was employed as an independent test dataset  
398 from a different clinical center.

399 To select the most relevant proteins (referred as “feature” in machine  
400 learning), we retrieved 174 significantly differentially expressed proteins from  
401 the proteomic profiling of SC and LC patients during the first three weeks  
402 (Table S3). These proteins were also identified in the independent test  
403 dataset. Then 58 features with highest predictive accuracy were prioritized  
404 from the training set using random forest (4.6.14) (Figure 6A, Figure S7A).  
405 After a six-fold cross-validation between the training set and the validation set,  
406 a classifier with 35 feature proteins was finalized for classifying LC patients  
407 with 100% accuracy in the training set (Figure 6A). The details of the 35 key  
408 features are shown in Figure 6B. Intercellular adhesion molecule 1 (ICAM1),  
409 low affinity immunoglobulin gamma Fc region receptor 3-A (FCGR3A) and  
410 immunoglobulin kappa variable 1-16 (IGKV1-16) are the top three ranked  
411 proteins, which were significantly regulated in LC patients within the first three  
412 weeks (Figure S7B). ICAM1 mediates cell-cell contact and promotes T cell  
413 apoptosis (Starke et al., 2010). FCGR3A is involved in antibody-dependent  
414 cell-mediated cytotoxicity (ADCC). The elevation of FCGR3A is consistent  
415 with the increase of NK cells in the LC group. IGKV1-16 is a part of the  
416 variable domain of immunoglobulin light chain, and it is secreted by B cell.  
417 IGKV1-16 was down-regulated in the LC group, which might be associated  
418 with dysregulation of B cell in the LC as discussed previously.

419 We then applied the model to the independent test cohort from a different  
420 clinical center. The model correctly classified 32 out of 39 patients with an  
421 overall accuracy of 82% (Figure 6C). Due to biosafety issues and the  
422 emergency of this pandemic, this study is limited by the sample size. We  
423 noticed that the distribution of samples in the different disease stage is  
424 different between discovery dataset and test dataset. The numbers of serum  
425 samples of the discovery dataset are 18, 31 and 31 for the first, second and  
426 the third week, respectively. However, the numbers for the test dataset are 21,  
427 14 and 4, showing substantially lower proportions in the second and third  
428 week. This difference was significant as measured by a two-sides Fisher’s  
429 exact test ( $p = 0.0004$ ). The substantially higher number of samples collected  
430 in the first week have probably contributed to the difficulty of correct  
431 classification by this model. Indeed, the prediction accuracy was 92.9% for the  
432 samples collected in the second and third weeks, while the accuracy was only  
433 72.2% for the samples collected in the first week. Future application and  
434 improvement of this model in larger clinical cohorts are needed.

## 435 **Conclusion**

436 COVID-19 patients with short and long disease courses showed no  
437 significant difference in clinical symptoms, laboratory tests and response to  
438 conventional therapy. Our longitudinal sera proteomic analysis uncovered  
439 characteristic host responses in sera of patients with long disease course,  
440 including enhanced NK cell-mediated innate immune response and Treg-  
441 mediated immunosuppression at an early stage. Our data also suggested  
442 CD3<sup>+</sup>CD56<sup>+</sup>CD16<sup>-</sup> cells might contribute to decreased production of S protein  
443 specific antibodies in the patients with a prolonged disease course. Our data  
444 suggest modulation of Treg cells may be potential therapeutics for these  
445 COVID-19 patients. We also showed that it is possible to predict the disease  
446 course of COVID-19 patients based on selected protein levels within the first  
447 three weeks after disease onset. The model nevertheless requires further  
448 validation in independent cohorts.  
449

## 450 **ACKNOWLEDGMENTS**

451 This work is supported by grants from Tencent Foundation (2020), National  
452 Natural Science Foundation of China (81972492, 21904107, 81672086),  
453 Zhejiang Provincial Natural Science Foundation for Distinguished Young  
454 Scholars (LR19C050001), and Hangzhou Agriculture and Society  
455 Advancement Program (20190101A04). We thank Drs O.L. Kon, H. Qi, H. Xu,  
456 and X. Chang for helpful comments to this study, and Westlake University  
457 Supercomputer Center and biomedical research core facilities for assistance  
458 in data generation and analysis.  
459

## 460 **AUTHOR CONTRIBUTIONS**

461 T.G., S.T., Y.Z. and J.H. designed and supervised the project. S.T., J.H.,  
462 T.M., C. H., S.L., X.X., H.L., L.W., J.D. collected the samples and clinical  
463 data. R.S., Q.X., W.G., M.L., L.Q., H.C., Q.Z., S.L., W.L., H.G., L.L., T.L.,  
464 X.L., X.C., and G.R. conducted proteomic analysis. T.M., Q.X. and R.S.  
465 performed flow cytometry analysis. R.S., Q.X., W.G., T.M., C.H., Y.Z., S.T.  
466 and T.G. interpreted the data with inputs from all co-authors. R.S., Q.X., Y.Z.  
467 and T.G. wrote the manuscript with inputs from co-authors.  
468

## 469 **DECLARATION OF INTERESTS**

470 This study is partly supported by Tecent.  
471

## 472 **REFERENCES**

473 Anguela, X.M., Tafuro, S., Roca, C., Callejas, D., Agudo, J., Obach, M., Ribera, A., Ruzo, A., Mann,  
474 C.J., Casellas, A., *et al.* (2013). Nonviral-mediated hepatic expression of IGF-I increases Treg  
475 levels and suppresses autoimmune diabetes in mice. *Diabetes* 62, 551-560.

- 476 Brown, J.A., Dorfman, D.M., Ma, F.R., Sullivan, E.L., Munoz, O., Wood, C.R., Greenfield, E.A., and  
477 Freeman, G.J. (2003). Blockade of programmed death-1 ligands on dendritic cells enhances T cell  
478 activation and cytokine production. *J Immunol* *170*, 1257-1266.
- 479 Cao, X. (2020). COVID-19: immunopathology and its implications for therapy. *Nat Rev Immunol*  
480 *20*, 269-270.
- 481 Colaert, N., Barsnes, H., Vaudel, M., Helsens, K., Timmerman, E., Sickmann, A., Gevaert, K., and  
482 Martens, L. (2011). Thermo-msf-parser: an open source Java library to parse and visualize  
483 Thermo Proteome Discoverer msf files. *J Proteome Res* *10*, 3840-3843.
- 484 di Comite, G., Marinosci, A., Di Matteo, P., Manfredi, A., Rovere-Querini, P., Baldissera, E., Aiello,  
485 P., Corti, A., and Sabbadini, M.G. (2006). Neuroendocrine modulation induced by selective  
486 blockade of TNF-alpha in rheumatoid arthritis. *Ann N Y Acad Sci* *1069*, 428-437.
- 487 Eissa, N., Hussein, H., Kermarrec, L., Ali, A.Y., Marshall, A., Metz-Boutigue, M.H., Hendy, G.N.,  
488 Bernstein, C.N., and Ghia, J.E. (2018). Chromogranin-A Regulates Macrophage Function and the  
489 Apoptotic Pathway in Murine DSS colitis. *J Mol Med (Berl)* *96*, 183-198.
- 490 Forman, H.J., Zhang, H., and Rinna, A. (2009). Glutathione: overview of its protective roles,  
491 measurement, and biosynthesis. *Mol Aspects Med* *30*, 1-12.
- 492 Gao, H., Zhang, F., Liang, S., Zhang, Q., Lyu, M., Qian, L., Liu, W., Ge, W., Chen, C., Yi, X., *et al.*  
493 (2020). Accelerated Lysis and Proteolytic Digestion of Biopsy-Level Fresh-Frozen and FFPE Tissue  
494 Samples Using Pressure Cycling Technology. *J Proteome Res* *19*, 1982-1990.
- 495 Goncalves, C.M., Castro, M.A., Henriques, T., Oliveira, M.I., Pinheiro, H.C., Oliveira, C., Sreenu, V.B.,  
496 Evans, E.J., Davis, S.J., Moreira, A., *et al.* (2009). Molecular cloning and analysis of SSc5D, a new  
497 member of the scavenger receptor cysteine-rich superfamily. *Mol Immunol* *46*, 2585-2596.
- 498 Hu, J., Yan, J., Rao, G., Latha, K., Overwijk, W.W., Heimerger, A.B., and Li, S. (2016). The Duality of  
499 Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant:  
500 Therapeutic Potential and Implications. *Int Rev Immunol* *35*, 325-339.
- 501 Huang, J.e.a. (2020). Long period dynamics of viral load and antibodies for SARS-CoV-2  
502 infection: an observational cohort study. medRxiv <https://doi.org/10.1101/2020.04.22.20071258>.
- 503 Ivetic, A., Deka, J., Ridley, A., and Ager, A. (2002). The cytoplasmic tail of L-selectin interacts with  
504 members of the Ezrin-Radixin-Moesin (ERM) family of proteins: cell activation-dependent  
505 binding of Moesin but not Ezrin. *J Biol Chem* *277*, 2321-2329.
- 506 Kemper, C., Chan, A.C., Green, J.M., Brett, K.A., Murphy, K.M., and Atkinson, J.P. (2003). Activation  
507 of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. *Nature* *421*,  
508 388-392.
- 509 Kimura, A., and Kishimoto, T. (2010). IL-6: regulator of Treg/Th17 balance. *Eur J Immunol* *40*,  
510 1830-1835.
- 511 Kumar, L., and Mattias, E.F. (2007). Mfuzz: a software package for soft clustering of microarray  
512 data. *Bioinformatics* *2*, 5-7.
- 513 Li, J., Van Vranken, J.G., Pontano Vaites, L., Schweppe, D.K., Huttlin, E.L., Etienne, C.,  
514 Nandhikonda, P., Viner, R., Robitaille, A.M., Thompson, A.H., *et al.* (2020). TMTpro reagents: a set  
515 of isobaric labeling mass tags enables simultaneous proteome-wide measurements across 16  
516 samples. *Nat Methods* *17*, 399-404.
- 517 Messner, e.a. (2020). Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19  
518 infection. *Cell Systems*, <https://doi.org/10.1016/j.cels.2020.1005.1012>.
- 519 Oida, T., Zhang, X., Goto, M., Hachimura, S., Totsuka, M., Kaminogawa, S., and Weiner, H.L.

520 (2003). CD4+CD25- T cells that express latency-associated peptide on the surface suppress  
521 CD4+CD45RB<sup>high</sup>-induced colitis by a TGF- $\beta$ -dependent mechanism. *J Immunol* *170*, 2516-  
522 2522.

523 Ruan, Q., Yang, K., Wang, W., Jiang, L., and Song, J. (2020). Clinical predictors of mortality due to  
524 COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med*  
525 *46*, 846-848.

526 Shen, B., *et al.* (2020). Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.  
527 medRxiv.

528 Starke, A., Lindenmeyer, M.T., Seegerer, S., Neusser, M.A., Rusi, B., Schmid, D.M., Cohen, C.D.,  
529 Wuthrich, R.P., Fehr, T., and Waeckerle-Men, Y. (2010). Renal tubular PD-L1 (CD274) suppresses  
530 alloreactive human T-cell responses. *Kidney Int* *78*, 38-47.

531 Thompson, A., Wolmer, N., Koncarevic, S., Selzer, S., Bohm, G., Legner, H., Schmid, P., Kienle, S.,  
532 Penning, P., Hohle, C., *et al.* (2019). TMTpro: Design, Synthesis, and Initial Evaluation of a Proline-  
533 Based Isobaric 16-Plex Tandem Mass Tag Reagent Set. *Anal Chem* *91*, 15941-15950.

534 To, K.K., Tsang, O.T., Leung, W.S., Tam, A.R., Wu, T.C., Lung, D.C., Yip, C.C., Cai, J.P., Chan, J.M.,  
535 Chik, T.S., *et al.* (2020). Temporal profiles of viral load in posterior oropharyngeal saliva samples  
536 and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.  
537 *Lancet Infect Dis*.

538 Ueda, Y., Katagiri, K., Tomiyama, T., Yasuda, K., Habiro, K., Katakai, T., Ikehara, S., Matsumoto, M.,  
539 and Kinashi, T. (2012). Mst1 regulates integrin-dependent thymocyte trafficking and antigen  
540 recognition in the thymus. *Nat Commun* *3*, 1098.

541 Wojtowicz, A., Gresnigt, M.S., Lecompte, T., Bibert, S., Manuel, O., Joosten, L.A., Rueger, S.,  
542 Berger, C., Boggian, K., Cusini, A., *et al.* (2015). IL1B and DEFB1 Polymorphisms Increase  
543 Susceptibility to Invasive Mold Infection After Solid-Organ Transplantation. *J Infect Dis* *211*,  
544 1646-1657.

545 Wu, D., Shu, T., Yang, X., Song, J.-X., Zhang, M., Yao, C., Liu, W., Huang, M., Yu, Y., Yang, Q., *et al.*  
546 (2020). Plasma Metabolomic and Lipidomic Alterations Associated with COVID-19. *National*  
547 *Science Review*.

548 Wu, Z., and McGoogan, J.M. (2020). Characteristics of and Important Lessons From the  
549 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases  
550 From the Chinese Center for Disease Control and Prevention. *JAMA*.

551 Yang, D., Rosenberg, H.F., Chen, Q., Dyer, K.D., Kurosaka, K., and Oppenheim, J.J. (2003).  
552 Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for  
553 dendritic cells. *Blood* *102*, 3396-3403.

554 Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., *et al.* (2020).  
555 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,  
556 China: a single-centered, retrospective, observational study. *Lancet Respir Med*.

557 Yang, Y., Bazhin, A.V., Werner, J., and Karakhanova, S. (2013). Reactive oxygen species in the  
558 immune system. *Int Rev Immunol* *32*, 249-270.

559 Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., *et al.* (2020).  
560 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:  
561 a retrospective cohort study. *Lancet* *395*, 1054-1062.

562 Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C., and  
563 Chanda, S.K. (2019). Metascape provides a biologist-oriented resource for the analysis of

564 systems-level datasets. Nat Commun *10*, 1523.

565

566

567

**Table 1. Baseline and progression of CVDTSA cohort**

Baseline Characteristic	non-COVID-19 (N=35)	COVID-19 SC (N=17)	COVID-19 LC (N=20)
<b>Gender — no. <sup>a</sup>(%)</b>			
male	17 (53.1)	8 (47.1)	11 (55.0)
female	15 (47.9)	9 (52.9)	9 (45.0)
<b>Age — yr <sup>b</sup></b>			
mean ± SD	43.0 ± 18.0	43.2 ± 10.5	49.0 ± 15.4
median (IQR)	37.5 (28.8-56.0)	44 (35.0-50.0)	50 (42.8-55.5)
range	18-80	27-67	2-84
<b>Symptoms —no. (%)</b>			
fever	28 (87.6)	10 (58.8)	14 (70.0)
cough	2 (6.3)	11 (64.7)	15 (75.0)
diarrhea	1 (3.1)	10 (58.8)	8 (40.0)
fatigue	1 (3.1)	8 (47.1)	7 (35.0)
<b>Comorbidities — no. (%)</b>			
hypertension		2 (11.8)	6 (30.0)
diabetes		0 (0.0)	3 (15.0)
hepatitis B		2 (11.8)	0 (0.0)
coronary sclerosis		0 (0.0)	3 (15.0)
gastrohelcosis		1 (5.9)	0 (0.0)
psoatic strain		0 (0.0)	1 (5.0)
chronic gynecologic inflammation		1 (5.9)	0 (0.0)
gout		0 (0.0)	1 (5.0)
asthma		0 (0.0)	1 (5.0)
<b>Treatment— no. (%)</b>			
lopinavir and ritonavir		17 (100.0)	19 (95.0)
Atomized interferon		17 (100.0)	20 (100.0)
Arbidol		7 (41.2)	12 (60.0)
Lianhuaqingwen (Chinese traditional medicine)		15 (88.2)	16 (80.0)
Ribavirin		0 (0.0)	3 (15.0)
Hydroxychloroquine		1 (5.9)	3 (15.0)

<sup>a</sup> no.: number.

<sup>b</sup> yr.: year

568

569

## 570 **Figure legend**

571 **Figure 1. Patients, samples and study workflow.** (A) Baseline  
572 characteristics of the study cohort. The y-axis shows the patient ID, and the x-  
573 axis displays the length of disease course from onset. The 37 patients are  
574 separated into SC (17 patients) and LC (20 patients) groups. Other important  
575 information including the virus nucleic acid test results (sputum/throat swab-  
576 positive/-negative), gender, severity, comorbidity baseline, etc., are shown in  
577 the right panel of the figure. The black dots indicate sampling time. More  
578 details are provided in Table S1. (B) Workflow for TMT based proteomic  
579 analysis in this study. 37 COVID-19 patients and 32 control (Ctrl) patients  
580 were included. In total, 224 sera samples were collected and 268 peptide  
581 samples including 44 technical replicates were analyzed by TMT 16plex-  
582 based quantitative proteomics.

583 **Figure 2. Complex immunity in the LC patients.** (A) Summary of enriched  
584 immune-related pathways in LC and SC patients across the disease course.  
585 Representative proteins involved in these pathways are also shown. (B) Venn  
586 diagram of differentially expressed proteins between the SC and LC groups  
587 over nine time points and specifically regulated in COVID-19 sera. (C)  
588 Heatmap of 97 dysregulated proteins in the SC and LC groups over nine time  
589 points. (D-E) Expression of protein group 1 and 2 across nine time points. The  
590 y-axis stands for the relative protein expression normalized by z-score. The  
591 pathways and representative participating proteins are shown below the  
592 boxplots.

593 **Figure 3. Characteristic proteins and pathways in LC patients.** (A)  
594 Representative proteins involved in leukocyte migration and IGF/redox  
595 homeostasis are plotted over time. (B) Diagram depicting that major regulated  
596 pathways in the LC patients including leukocytes migration and IGF/redox  
597 homeostasis jointly modulate Treg-mediated immunosuppression.

598 **Figure 4. Flow cytometric analysis of immune cells between SC and LC**  
599 **patients.** 22 samples from 17 LC patients and 30 samples from 17 SC  
600 patients were analyzed. (A) Flow cytometric analysis of lymphocytes, CD4+  
601 cells and CD127-CD25+ Treg cells of two representative patients. Bean plots  
602 show the comparison between the two groups. (B) Flow cytometric analysis of  
603 lymphocytes, CD8+ cells and CD56+CD16+ NK cells of two representative  
604 patients. Bean plots show the comparison between the two groups.

605 **Figure 5. Dynamics of IL6ST, IL6R, LAP3 and TGFB1 in SC and LC**  
606 **patients.** (A) Proteins detected by MS-based proteomics. (B) Violin plot  
607 showed that cytokines detected by antibody-based flow cytometric analysis  
608 (24 samples from 13 SC patients and 19 samples from 12 LC patients).

609 **Figure 6. Machine learning model for predicting disease course.** (A)  
610 Workflow for machine learning. (B) The top 35 key feature proteins selected  
611 by the machine learning model. (C) The validation of the model in an  
612 independent test dataset.



613 **STAR★METHODS**

614 **KEY RESOURCES TABLE**

<b>REAGENT or RESOURCE</b>	<b>SOURCE</b>	<b>IDENTIFIER</b>
<b>Biological Samples</b>		
<b>Serum samples from 37 COVID-19 patients and 34 non-COVID-19 patients</b>	Wenzhou Central Hospital	This paper
<b>Chemicals, Peptides, and Recombinant Proteins</b>		
<b>Triethylammonium bicarbonate buffer (TEAB)</b>	Sigma-Aldrich	Cat # T7408
<b>Pierce™ Micro-spin column</b>	Thermo Fisher Scientific	Cat # 89868
<b>High Select™ Top14 abundant protein depletion resin</b>	Thermo Fisher Scientific	Cat # A36372
<b>3K MWCO pierce protein concentrators</b>	Thermo Fisher Scientific	Cat # 88521
<b>Urea</b>	Sigma-Aldrich	Cat # U1250
<b>Tris (2-carboxyethyl) phosphine (TCEP)</b>	Adamas-beta	Cat # 61820E
<b>Iodoacetamide (IAA)</b>	Sigma-Aldrich	Cat # I6125
<b>Trypsin</b>	Hualishi Tech	Cat # HLS TRY001C
<b>Trifluoroacetic acid (TFA)</b>	Thermo Fisher Scientific	Cat # 85183
<b>Water</b>	Thermo Fisher Scientific	Cat # W6-4
<b>Acetonitrile</b>	Thermo Fisher Scientific	Cat # A955-4
<b>Formic acid (FA)</b>	Thermo Fisher Scientific	Cat # A117-50
<b>Ammonium hydroxide solution</b>	Sigma-Aldrich	Cat # 221228
<b>Methanol</b>	Sigma-Aldrich	Cat # 34860
<b>Critical Commercial Assays</b>		
<b>TMTpro™ 16plex reagents</b>	Thermo Fisher Scientific	Cat # A44520
<b>SARS-CoV-2 nucleic acid detection kit</b>	Shanghai BioGerm Medical Technology	Cat # 20200125E
<b>CD4-PE-Cy7</b>	UB Biotechnology	Cat # UB105441
<b>CD3-FITC</b>	UB Biotechnology	Cat # UB104411
<b>CD25-PE</b>	UB Biotechnology	Cat # UB112421
<b>CD45-PerCP-Cy5.5</b>	UB Biotechnology	Cat # UB109481
<b>CD127-APC</b>	UB Biotechnology	Cat # UB113451
<b>CD8-PE</b>	UB Biotechnology	Cat # UB106421
<b>CD16-PE-Cyanine7</b>	UB Biotechnology	Cat # UB107441
<b>CD56-PE</b>	UB Biotechnology	Cat # UB108421
<b>Cytokines detection kit including IL-2/IL-4/IL-5/IL-6/IL-10/IL-17A/TNF-α/IFN-γ</b>	UB Biotechnology	Cat # UB06PX

<b>Software and Algorithms</b>		
<b>Xcalibur</b>	Thermo Fisher Scientific	Cat # OPTON-30965
<b>Proteome Discoverer Version 2.4.1.15</b>	Thermo Fisher Scientific	<a href="https://www.thermofisher.com/hk/en/home/industrial/mass-spectrometry/liquid-chromatography-mass-spectrometry-lc-ms/lc-ms-software/multi-omics-data-analysis/proteome-discoverer-software.html">https://www.thermofisher.com/hk/en/home/industrial/mass-spectrometry/liquid-chromatography-mass-spectrometry-lc-ms/lc-ms-software/multi-omics-data-analysis/proteome-discoverer-software.html</a>
<b>R version 3.6.1</b>	R Project	<a href="https://www.r-project.org">https://www.r-project.org</a>
<b>Ingenuine pathway analysis (version 51963813)</b>	Kramer et al., 2014	<a href="https://www.qiagen.com/cn/">https://www.qiagen.com/cn/</a>
<b>Kaluza analysis soft version 2.1</b>	Beckman coulter life sciences	Cat # A82959
<b>NovoExpress version 1.4.1</b>	Agilent Bio	<a href="https://www.aceabio.com/products/novoexpress-software/">https://www.aceabio.com/products/novoexpress-software/</a>
<b>Other</b>		
<b>SOLA<math>\mu</math></b>	Thermo Fisher Scientific	Cat # 62209-001
<b>ACQUITY UPLC Systems with 2D LC Technology</b>	Waters Corporation	Cat # 186015001
<b>ACQUITY BEH C18 column, 2.1 <math>\times</math> 100 mm, 1.7 <math>\mu</math>m</b>	Waters Corporation	Cat # 186008316
<b>ACQUITY BEH Amide column, 2.1 <math>\times</math> 100 mm, 1.7 <math>\mu</math>m</b>	Waters Corporation	Cat # 186008315

615

## 616 **RESOURCE AVAILABILITY**

### 617 **Lead contact**

618 Further information should be directed to and will be fulfilled by the Lead  
619 Contact Tiannan Guo ([guotiannan@westlake.edu.cn](mailto:guotiannan@westlake.edu.cn)).

620

### 621 **Materials Availability**

622 This study did not generate new unique reagents.

623

### 624 **Data Availability**

625 All data are available in the manuscript or the supplementary material. The  
626 proteomics data are deposited in ProteomeXchange Consortium  
627 (<https://www.iprox.org/>). Project ID: IPX0002170000.

628

629

## 630 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

### 631 **Patients and sera samples**

632 We procured 72 patients in this study, including 37 COVID-19 patients  
633 whose sputa or throat swabs were tested positive for SARS-CoV-2  
634 according to the manufacturer's instructions (Shanghai BioGerm Medical  
635 Technology Co., LTD, Shanghai, China). According to the Chinese  
636 Government Diagnosis and Treatment Guideline (Trial 4th version) (Shen,  
637 2020), these 37 COVID-19 patients include 35 typical cases and two severe  
638 cases. We have also procured 35 non-COVID-19 patients showing similar  
639 flu-like clinical symptoms to COVID-19 patients with negative nucleic acid  
640 testing for SARS-CoV-2. More details of these patients are provided in  
641 Figure 1A and Table S1.

642 We defined the disease onset as the day when the patient manifests  
643 clinical symptoms, while the disease recovery as the day when nucleic acid  
644 test of sputa or throat swab turns negative, and negative for the second test  
645 after a minimal interval of 24 hours, the same test is still negative. The  
646 disease course was thus defined as the period between disease onset and  
647 disease recovery.

648 Totally 224 sera samples from these patients were collected  
649 longitudinally for proteomics analysis (Figure 1B, Table S1). Sampling was  
650 performed in the early morning before diet using serum separation tubes  
651 (BD, USA). The blood was clotted for about 30 min at room temperature,  
652 and then centrifuged at 1000 g for ten min for serum sample collection. This  
653 study has been registered in the Chinese Clinical Trial Registry with an ID of  
654 ChiCTR2000031699. This study has been approved by the  
655 Ethical/Institutional Review Board of Wenzhou Central Hospital and Westlake  
656 University. Contents from patients were waived by the boards.

657

## 658 **METHOD DETAILS**

659

### 660 **Proteome analysis**

661 Serum samples were prepared as previously described (Shen, 2020).  
662 Briefly, serum samples were firstly inactivated and sterilized at 56 °C for 30  
663 mins. For proteomic study, 4 µL of serum was used for each sample. The  
664 serum was firstly depleted of 14 high abundant serum proteins using a  
665 human affinity depletion kit (Thermo Fisher Scientific™, San Jose, USA).  
666 After depletion, the serum solution was concentrated into 50 µL through a 3k  
667 MWCO filtering unit (Thermo Fisher Scientific™, San Jose, USA) according  
668 to manufacturer. And then was mixed with 500 µL 8 M urea (Sigma) and  
669 concentrated into 50 µL. Then proteins were reduced and alkylated with 10  
670 mM tris (2-carboxyethyl) phosphine (TCEP, Sigma) and 40 mM  
671 iodoacetamide (IAA), respectively. Proteins were submitted to two times of  
672 tryptic digestion (enzyme to protein ratio: 1:20; Hualishi Tech. Ltd, Beijing,  
673 China). The digestion was then stopped with 1% trifluoroacetic (TFA)  
674 (Thermo Fisher) to pH 2–3 to stop the reaction, and peptides were subjected  
675 to C18 (Thermo Fisher) desalting.

676 TMT 16-plex (Thermo Fisher) reagents were applied to label the digested  
677 peptides. The TMT labeled samples were further fractionated along a 2 hr  
678 basic pH reverse phase LC gradient using a Dinex Ultimate 3000 UHPLC  
679 (Thermo Fisher) (Li et al., 2020). LC-MS/MS analysis was performed using  
680 the Easy-nLC™ 1200 nanoLC-MS/MS system (Thermo Fisher) or a Dinex  
681 Ultimate 3000 UHPLC coupled to a Q Exactive HF or HF-X (Thermo Fisher),  
682 along a 60 min LC gradient at a flowrate of 300 nL/min as described  
683 previously (Gao et al., 2020; Shen, 2020). To reach comparable proteomic  
684 depth, the fractionated samples were combined into 30 fractions for analysis  
685 in QE-HF instruments and 26 for QE-HFX instruments.

686

### 687 **Database search and statistical analysis**

688 MS data was performed using Proteome Discoverer (Version 2.4.1.15,  
689 Thermo Fisher) (Colaert et al., 2011) search engine against the human  
690 protein database downloaded from UniProt (version 02/01/2020; 164,930  
691 sequences), with a precursor ion mass tolerance of 10 ppm and fragment ion  
692 mass tolerance of 0.02 Da. Please see previous paper (Shen, 2020) for  
693 detailed parameters of the database searching. Briefly, TMT pro-plex labels  
694 to lysine and N-terminus, and carbamidomethylation of cysteine were set as  
695 static modifications. A cut-off criterion of a q-value of 0.01, corresponding to  
696 a 1% false-discovery rate (FDR) was set for the filtered of identified peptides  
697 with highly confident peptide hits.

698 After filtering 80% missing rate proteins, 2700 proteins used for  
699 differential expression analysis based on  $|\log_2(\text{FC})|$  and two-sided unpaired  
700 Welch's t test. The created missing values were imputed with zero.

701

## 702 **Pathway analysis**

703 For the pathway enrichment analysis, firstly, four databases including  
704 KEGG pathway, GO biological processes, Reactome gene sets and  
705 immunologic signatures were used for immune characterization analysis on  
706 the Metascape web-based platform (Zhou et al., 2019). IPA was then used  
707 to look at the pathways for differentially expressed proteins.

708

## 709 **Statistical analysis**

710 Two-sided unpaired Welch's t test was performed for each pair of  
711 comparing groups. The one-way analysis of variance (ANOVA) was used to  
712 performed among nine time points. Adjusted p values were calculated using  
713 Benjamini & Hochberg correction.

714

## 715 **Machine learning**

716 The machine learning was performed using the R package randomForest  
717 (version 4.6.14) as described previously with some modifications (Shen,  
718 2020) as described briefly in the following. The discovery dataset was divided  
719 into two parts, *i.e.* the training set and the validation set. We optimized the key  
720 random forest parameters including the cutoff values for decrease mean  
721 accuracy, cross-validation fold, and the number of trees. Input protein features  
722 were selected based on the mean decrease accuracy cutoff. For the  
723 optimized model, the minimal mean decrease accuracy of protein features  
724 was 2, the mtry was set as 13, and 800 trees were built. Six-fold cross  
725 validation was performed and this was repeated 100 times.

726

## 727 **Flow cytometry analysis**

728 Peripheral blood samples from EDTA anticoagulants were incubated with  
729 mixture antibodies including CD4-PE-Cy7 (UB105441, UB Biotechnology Co.,  
730 Ltd, Hangzhou, China), CD3-FITC (UB104411), CD25-PE (UB112421),  
731 CD45-PerCP-Cy5.5 (UB109481), CD127-APC (UB113451) and a kit  
732 (UB06PX) for cytokines detection including IL-2/IL-4/IL-5/IL-6/IL-10/IL-  
733 17A/TNF- $\alpha$ /IFN- $\gamma$  for 15 min at room temperature. Double negative control  
734 and single-stain controls were prepared by normal samples, and were used to  
735 calculate a compensation matrix. Sample acquisition was performed on a  
736 Gallios (Beckman Coulter) cytometer equipped. Final analysis and graphical  
737 output were performed using NovoExpress software (Agilent Bio).

738

## 739 SUPPLEMENTARY FIGURE LEGEND

740 **Figure S1. Correlation analysis between the SC and LC group based on**  
741 **clinical data, Related to Figure 1. (A)** Boxplot of patient ages. Ctrl (N=35),  
742 SC (N=17) and LC(N=20). **(B)** Heatmap shows medication history in SC and  
743 LC groups. The column set on the right represents the drugs and relevant p  
744 value showing medication difference between the two groups (two-sided  
745 Fisher. test). **(C)** Comparison of blood test results between SC (N=17) and LC  
746 (N=15) patients. Boxplots display the blood biochemistry tests based on  
747 samples collected on the first day in the hospital.

748 **Figure S2. Quality assessment of proteomics data. Related to Figure 1.**  
749 **(A)** Batch design of proteomic analysis. All 268 peptide samples are randomly  
750 separated into 18 batches for TMTpro labeling and MS analysis. **(B)** The  
751 median technical CV of the proteomics data is calculated by the identified  
752 proteins in 44 technical replicates.

753 **Figure S3. Pathway enrichment analysis at nine time points using**  
754 **differentially expressed proteins between the SC and LC group, Related**  
755 **to Figure 2.** Pathways were enriched using Metascape. The pathways in the  
756 blue box are not directedly related to immunity.

757 **Figure S4. The dynamic expression of proteins across the entire disease**  
758 **course between SC and LC, Related to Figure 2.** The x-axis shows the  
759 week index, while the y-axis denotes protein expression ratio from the TMT  
760 experiment. Pair-wise comparison of each proteins in the two patient groups  
761 was performed with student's *t* test. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ .



762 **Figure S5. Eight clusters of proteins showing temporal dynamics by**  
763 **Mfuzz analysis in the SC and LC group, Related to Figure 4.** Proteins  
764 detected in SC **(A)** and LC **(B)** are grouped into eight clusters with different  
765 quantitative patterns over the disease course. ANOVA analysis was performed  
766 in each cluster (the cutoff of the adjusted p value (BH adjust) was 0.05). **(C)**  
767 Upset plots shows the overlapping protein clusters selected by Mfuzz.

768 **Figure S6. Flow cytometric analysis of lymphocytes, CD3- cells, Related**  
769 **to Figure 4.** 22 samples from 17 LC patients and 30 samples from 17 SC  
770 patients were measured and analyzed. **(A)** Results of lymphocytes, CD3-  
771 cells, i.e. P14 (SC) and P15 (LC). **(B)** Bean plots show the comparison of cell  
772 populations between patient groups. **(C)** Violin plots show cytokines detected  
773 by antibody-based flow cytometric analysis (24 samples from 13 SC patients  
774 and 19 samples from 12 LC patients). The y-axis shows the intensity of each  
775 cytokine.

776 **Figure S7. 58 key feature proteins and the expression of top three**  
777 **proteins, ICAM1, FCGR3A and IGKV1-16. Related to Figure 6 (A)** 58  
778 features ranking according to mean decrease accuracy. **(B)** Protein  
779 expression of ICAM1, FCGR3A and IGKV1-16 between SC and LC groups in  
780 discovery dataset test dataset, respectively.

781


782 Figure 1



783

784

785 Figure 2




786

787

788




789 Figure 3



790

791


792 Figure 4



793

794


795 Figure 5



796


797

798 Figure 6



799  
800  
801

802 Figure S1



803


804

805 Figure S2

A

	B1	B2	B3	B4	B5	B6	B7	B8	B9	B10	B13	B14	B15	B16	B17	B18	B19	B20
126	Pool 1	Pool 1	Pool 1	Pool 1	Pool 1	Pool 1	Pool 1	Pool 1	Pool 1	Pool 1	Pool 1	Pool 2	Pool 2	Pool 2	Pool 2	Pool 1	Pool 1	Pool 1
127C	P23_2	P5_2	P25_1	P29_2	P13_1	P26_1	P7_1	P2_2	P34_4	Pool 2	Pool 2	P10_1B	P22_1B	P23_7	P18_4	P29_5	P26_5	P33_8
127N	P23_3	P5_3	P25_2	P29_3	P13_2	P26_2	P7_2	P2_3	P35_7	P33_7	P2_2B	P10_2C	P22_2B	P23_8	P5_7	P29_6	P28_5	P33_9
128C	P23_5	P9_4	P25_4	P29_4	P13_3	P26_3	P7_3	P27_2	P35_6	P33_5	P2_3B	P10_3B	P22_3B	P20_8	P5_9	P29_8	P28_4	P33_10
128N	P20_3	P17_2	P8_1	P30_1	P10_1	P21_1	P32_2	P27_3	P36_7	P33_6	P2_4B	P10_4	P22_4	P20_9	P8_3B	P30_5	P28_7	P16_4
129C	P20_4	P17_3	P8_2	P30_2	P10_2	P21_2	P32_3	P27_4	P36_5	P10_6	P2_5B	P10_6B	P22_9	P6_6	P25_5	P30_6	P7_5	P16_5
129N	P20_5	P17_4	P8_3	P30_3	P10_3	P21_3	P32_4	P16_1	P37_6	P10_2B	P2_6C	P21_1B	P24_1B	P6_7	P25_6	P15_4	P7_6	P16_6
130C	P6_2	P22_1	P3_2	P18_1	P14_1	P24_1	P1_2	P16_2	Ctrl_1	P2_4	P2_7	P21_2B	P24_2B	P6_9	P25_8	P15_5	P7_8	P16_8
130N	P6_3	P22_2	P3_3	P18_2	P14_2	P24_2	P1_3	P16_3	P2_6	P2_6B	P32_2B	P21_3B	P24_3B	P31_4	P8_4	P15_6	P12_4	P19_6
131C	P6_4	P22_3	P3_4	P18_3	P14_3	P24_3	P12_1	P19_2	P36_7B	P2_5	P32_3B	P21_4	P24_4	P31_5	P8_5	P15_8	P12_5	P19_7
131N	P31_1	Ctrl_5	P11_1	P15_1	Ctrl_12	P28_1	P12_2	P19_3	P7_3B	Ctrl_2B	P32_4B	P21_5	P24_5	P31_7	P8_7	P13_4	P12_6	P19_9
132C	P31_2	Ctrl_16	P11_2	P15_2	Ctrl_35	P28_2	P12_3	P19_4	P18_2B	Ctrl_6B	P32_6	P21_6	P24_6	P35_9	P11_4	P13_6	P12_8	P2_2C
132N	P31_3	Ctrl_32	P11_3	P15_3	Ctrl_34	P28_3	Ctrl_18	Ctrl_30	P22_3B	Ctrl_26B	P32_8	P1_5	P24_8	P36_8	P11_5	P13_8	P9_5	P4_6
133C	Ctrl_6	Ctrl_27	Ctrl_3	Ctrl_4	Ctrl_22	Ctrl_10	Ctrl_11	Ctrl_23	Ctrl_14	P21_3C	Ctrl_6B	P1_6	P3_5	P36_9	P11_6	P14_4	P12_3B	P4_8
133N	Ctrl_13	Ctrl_17	Ctrl_24	Ctrl_25	Ctrl_29	Ctrl_36	Ctrl_8	Ctrl_9	Ctrl_15	P25_4B	Ctrl_13B	P1_8	P3_7	P20_5B	P11_8	P14_5	P37_9	P22_5
134N	Ctrl_31	Ctrl_33	Ctrl_26	Ctrl_21	Ctrl_7	Ctrl_19	Ctrl_28	Ctrl_20	Ctrl_1B	P19_4B	Ctrl_31B	Ctrl_27B	P3_8	P10_3C	P5_6	P14_7	P34_7	P16_2B


B



806


807

808 Figure S3



809


810



811  
812




813 Figure S4



814

815

816 Figure S5




817

818


819

820 Figure S6



821

822 Figure S7



823

824